Home » News » Drug Sponsors » Lilly CEO confident in FDA approval

Lilly CEO confident in FDA approval

Monday, March 14, 2011

Eli Lilly CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease, according to a Bloomberg News report.

Outside advisers to the FDA voted in January against immediate approval of the medicine, Amyvid, unless the Indianapolis-based drug maker established a training program and a way to ensure that results of brain scans are read consistently. Lilly aims to resolve the FDA panel’s concerns in a few months, Lechleiter said in an interview.

“We are confident that we can work with the FDA and gain approval,” Lechleiter, 57, said in the Bloomberg report. “This is an imaging agent that we’ve used in our own clinical studies, so we are very familiar with it.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!